- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07590362
D-RSBI Versus RSBI for Predicting Weaning Success in COPD Patients
May 14, 2026 updated by: Ahmed Atef Mohamed, Sohag University
Diaphragmatic Rapid Shallow Breathing Index (D-RSBI) Versus Traditional Rapid Shallow Breathing Index (RSBI) for Prediction of Weaning Success From Mechanical Ventilation in COPD Patients
This prospective observational cohort study aims to compare the predictive accuracy of diaphragmatic rapid shallow breathing index (D-RSBI) versus traditional rapid shallow breathing index (RSBI) for predicting weaning success from invasive mechanical ventilation in COPD patients.
Diaphragmatic ultrasound measurements will be performed during spontaneous breathing trials, and patients will be followed for 72 hours after extubation to assess weaning outcomes.
Study Overview
Status
Recruiting
Study Type
Observational
Enrollment (Estimated)
100
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ahmed Atef Mohamed, MBBCh
- Phone Number: +201006973892
- Email: ahmed_ateff_post@med.sohag.edu.eg
Study Locations
-
-
Sohag Governorate
-
Sohag, Sohag Governorate, Egypt, 82524
- Recruiting
- Sohag University Hospital
-
Contact:
- Ahmed Atef Mohamed Sayed, MBBCh
- Phone Number: +2001006973892
- Email: atef53370@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Mechanically ventilated adult COPD patients admitted to the intensive care units of Sohag University Hospitals and fulfilling standard weaning readiness criteria.
Description
Inclusion Criteria:
- Mechanically ventilated COPD patients fulfilling standard weaning readiness criteria.
- Invasive mechanical ventilation for more than 24 hours before spontaneous breathing trial.
- Hemodynamically stable without significant vasopressor support.
- Adequate oxygenation with FiO2 ≤ 0.5 and PEEP ≤ 8 cmH2O .
- Preserved mental status and ability to initiate spontaneous breathing.
- Successful tolerance of spontaneous breathing trial conducted on CPAP mode with pressure support ≤ 8 cmH2O.
Exclusion Criteria:
- Refusal of consent
- Neuromuscular disease, phrenic nerve palsy, or diaphragmatic paralysis.
- Large pneumothorax or pathology interfering with ultrasound assessment.
- Terminal extubation.
- Recent major thoracic surgery.
- Poor sonographic window despite repeated attempts.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Mechanically Ventilated COPD Patients
COPD patients receiving invasive mechanical ventilation who fulfill weaning readiness criteria and undergo spontaneous breathing trial with assessment of D-RSBI and conventional RSBI.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
AUROC of D-RSBI for prediction of successful weaning
Time Frame: Within 72 hours after extubation
|
Area under the receiver operating characteristic curve (AUROC) of diaphragmatic rapid shallow breathing index (D-RSBI) for predicting successful weaning within 72 hours after extubation in mechanically ventilated COPD patients.
|
Within 72 hours after extubation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
AUROC of conventional RSBI for prediction of successful weaning.
Time Frame: Within 72 hours after extubation
|
Area under the receiver operating characteristic curve (AUROC) of conventional rapid shallow breathing index (RSBI) for predicting successful weaning within 72 hours after extubation in mechanically ventilated COPD patients.
|
Within 72 hours after extubation
|
|
Difference between AUROC values of D-RSBI and conventional RSBI
Time Frame: Within 72 hours after extubation
|
Comparison between AUROC values of D-RSBI and conventional RSBI for prediction of successful weaning.
|
Within 72 hours after extubation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Llamas-Alvarez AM, Tenza-Lozano EM, Latour-Perez J. Diaphragm and Lung Ultrasound to Predict Weaning Outcome: Systematic Review and Meta-Analysis. Chest. 2017 Dec;152(6):1140-1150. doi: 10.1016/j.chest.2017.08.028. Epub 2017 Aug 31.
- Spadaro S, Grasso S, Mauri T, Dalla Corte F, Alvisi V, Ragazzi R, Cricca V, Biondi G, Di Mussi R, Marangoni E, Volta CA. Can diaphragmatic ultrasonography performed during the T-tube trial predict weaning failure? The role of diaphragmatic rapid shallow breathing index. Crit Care. 2016 Sep 28;20(1):305. doi: 10.1186/s13054-016-1479-y.
- Yang KL, Tobin MJ. A prospective study of indexes predicting the outcome of trials of weaning from mechanical ventilation. N Engl J Med. 1991 May 23;324(21):1445-50. doi: 10.1056/NEJM199105233242101.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 15, 2026
Primary Completion (Estimated)
May 1, 2027
Study Completion (Estimated)
June 1, 2027
Study Registration Dates
First Submitted
May 7, 2026
First Submitted That Met QC Criteria
May 14, 2026
First Posted (Actual)
May 15, 2026
Study Record Updates
Last Update Posted (Actual)
May 15, 2026
Last Update Submitted That Met QC Criteria
May 14, 2026
Last Verified
May 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Soh-Med-26-4-1MS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease (COPD)
-
Ryme Medical, Inc.Not yet recruitingCOPD | Lung Disease, Chronic Obstructive | COPD Patients | COPD Acute Exacerbation | COPD (Chronic Obstructive Pulmonary Disease) | Lung Disease Airways | COPD Exacerbations
-
University College, LondonUniversity of Cambridge; National Institute for Health Research, United Kingdom and other collaboratorsUnknownChronic Obstructive Pulmonary Disease (COPD).United Kingdom
-
Virginia Commonwealth UniversityFisher and Paykel HealthcareCompletedChronic Obstructive Pulmonary Disease(COPD)United States
-
Morair Medtech, LLCRecruitingEmphysema | COPD | Emphysema or COPD | COPD (Chronic Obstructive Pulmonary Disease) | Emphysema, PulmonaryAustria, Germany, Netherlands
-
Reham Mohammed ElmorshedyCompletedChronic Obstructive Pulmonary Disease(COPD)Egypt
-
AstraZenecaCompletedChronic Obstructive Pulmonary Disease (COPD).United Kingdom
-
Medtronic BRCUnknownCOPD | COPD Exacerbation
-
Beaumont HospitalAerogenCompletedChronic Obstructive Pulmonary Disease | COPD | COPD Exacerbation | Copd Exacerbation AcuteIreland
-
Chiesi Farmaceutici S.p.A.CompletedModerate to Severe Chronic Obstructive Pulmonary Disease (COPD)Bulgaria, Germany, Hungary, Poland, Russian Federation, United Kingdom
-
Barron Associates, Inc.National Heart, Lung, and Blood Institute (NHLBI); University of VirginiaNot yet recruitingCOPD | COPD - Chronic Obstructive Pulmonary DiseaseUnited States